Aficamten fda approval status 2026?

Has Aficamten been approved by the FDA yet (for 2026)?

Yes. Aficamten (brand name Camzyos) has FDA approval for certain patients with symptomatic obstructive hypertrophic cardiomyopathy (HCM). The FDA’s approval status and labeling are maintained on the FDA’s drug database. [1][2]

What FDA approval does the label cover (indication and patient population)?

Aficamten’s FDA approval is for adults with symptomatic obstructive hypertrophic cardiomyopathy. It is used as part of a structured treatment approach that includes cardiac monitoring because the drug can reduce cardiac contractility. The approved indication, dosing framework, and required monitoring requirements are described in the FDA-approved prescribing information. [1][2]

What dosing/monitoring requirements matter for 2026 patients?

FDA labeling requires monitoring tied to the drug’s effect on cardiac function. The prescribing information outlines the need for echocardiographic assessment and dose adjustments/hold-and-restart steps based on response. These requirements are central to continued safe use under the approved regimen. [1][2]

Where can I check the most current FDA status and label updates?

For the most up-to-date FDA status in 2026, check:
- FDA’s “Drugs@FDA” listing for Aficamten (Camzyos). [1]
- The FDA-approved prescribing information for Camzyos, which reflects current labeling. [2]

What if you meant “approval for a new use” rather than the original FDA approval?

FDA approval status can differ by whether you mean:
- initial approval for the current indication (already approved), or
- expansion to a new patient subgroup/indication, dosing change, or new form.
Those updates would appear in Drugs@FDA and in revisions to the label on the prescribing information page. [1][2]

Sources

1. Drugs@FDA: Camzyos (aficamten)
   
2. FDA Prescribing Information: Camzyos (aficamten)